Escherichia coli in the production of biopharmaceuticals
Biotechnology and Applied Biochemistry · 2025-04 · 72 (2) · 528-541
DOI: 10.1002/bab.2664 ↗At a glance
Übersichtsarbeit in Biotechnology and Applied Biochemistry, published online on 2024-09-08. Written by İbrahim İncir and 1 co-authors. Institution: Kazım Karabekir Vocational School, Department of Medical Services and Techniques, Environmental Health Program, Karamanoğlu Mehmetbey University, Kar…. Major MEDLINE topics: Escherichia coli, Biological Products, Recombinant Proteins. Cited 30 times so far (Crossref); 119 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the US Food and Drug Administration and the European Medicines Agency to treat various human diseases. Although E. coli has some disadvantages, such as lack of post‐translational modifications and toxicity, it is an important host with advantages such as being a well‐known bacterium in recombinant protein production, cheap, simple production system, and high yield. This study examined biopharmaceuticals produced and approved in E. coli under the headings of peptides, hormones, enzymes, fusion proteins, antibody fragments, vaccines, and other pharmaceuticals. The topics on which these biopharmaceuticals were approved for treating human diseases, when and by which company they were produced, and their use and development in the field are included.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Kazım Karabekir Vocational School, Department of Medical Services and Techniques, Environmental Health Program, Karamanoğlu Mehmetbey University, Karaman, Turkey.
- Rafet Kayış Faculty of Engineering, Department of Genetics and Bioengineering, Alanya Alaaddin Keykubat University, Antalya, Turkey.
ORCID profiles: İbrahim İncir
Cite
APA
İncir, İ., & Kaplan, Ö. (2025). Escherichia coli in the production of biopharmaceuticals. Biotechnology and Applied Biochemistry, 72(2), 528-541. https://doi.org/10.1002/bab.2664
Vancouver
İncir İ, Kaplan Ö. Escherichia coli in the production of biopharmaceuticals. Biotechnology and Applied Biochemistry. 2025;72(2):528-541. doi:10.1002/bab.2664
BibTeX
@article{ncir2025,
author = {İncir, İbrahim and Kaplan, Özlem},
title = {Escherichia coli in the production of biopharmaceuticals},
journal = {Biotechnology and Applied Biochemistry},
year = {2025},
volume = {72},
number = {2},
pages = {528--541},
doi = {10.1002/bab.2664}
}
EUVIMED